GLU-xx Formulations in Individuals With Impaired Glucose Tolerance
Phase 1
Terminated
- Conditions
- Impaired Glucose Tolerance
- Interventions
- Dietary Supplement: GLU-01Dietary Supplement: GLU-02Dietary Supplement: GLU-03Dietary Supplement: GLU-04Dietary Supplement: GLU-05Dietary Supplement: GLU-06
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Afexa Life Sciences Inc
- Target Recruit Count
- 17
- Registration Number
- NCT01468376
- Locations
- πΊπΈ
Staywell Research LLC, Northridge, California, United States
Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2012-01-25
- Lead Sponsor
- Afexa Life Sciences Inc
- Registration Number
- NCT01456182
- Locations
- πΊπΈ
Saint Jospeh Mercy Health System, Ann Arbor, Michigan, United States
πΊπΈComprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
πΊπΈCancer Center of the Carolinas, Greenville, South Carolina, United States
A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population
Phase 2
Completed
- Conditions
- Upper Respiratory Tract Infections
- Interventions
- Other: North American ginsengOther: Placebo
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- Afexa Life Sciences Inc
- Target Recruit Count
- 293
- Registration Number
- NCT00965822
- Locations
- π¨π¦
JDM Research, Toronto, Ontario, Canada
π¨π¦Alberta Health Services, Edmonton, Alberta, Canada
π¨π¦Saint John Regional Hospital, Saint John, New Brunswick, Canada
LIP-01 in Hypercholesterolemia
Phase 1
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Dietary Supplement: LIP-01
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Afexa Life Sciences Inc
- Target Recruit Count
- 40
- Registration Number
- NCT00966225
- Locations
- πΊπΈ
Medicus Research, LLC, Northridge, California, United States
π¨π¦The Northern Alberta Clinical Trials and Research Centre, Edmonton, Alberta, Canada
A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2010-10-11
- Lead Sponsor
- Afexa Life Sciences Inc
- Target Recruit Count
- 200
- Registration Number
- NCT00726401
- Locations
- π¨π¦
Melimar Allergy Laboratory, Toronto, Ontario, Canada
π¨π¦JDM Research, Toronto, Ontario, Canada
π¨π¦Capital Health, Edmonton, Alberta, Canada
Β© Copyright 2025. All Rights Reserved by MedPath